autologous alpha-beta T-cell receptor targeting survivin (Baylor College of Medicine)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameautologous alpha-beta T-cell receptor targeting survivin (Baylor College of Medicine)

Drug Alias Nameanti-survivin TCR T-cell therapy Baylor College of Medicine

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionHuman leukocyte antigen modulatorsBaculoviral IAP repeat-containing protein 5 modulators

TargetsBaculoviral IAP repeat-containing protein 5Human leukocyte antigen

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBaylor College Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBaylor College Of Medicine

Active IndicationsN/A

Inactive IndicationsHematologic Neoplasms

Other Information

ATC CodeN/A